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ABSTRACT: Background. Despite better prognosis, there is a group of
oropharyngeal squamous cell carcinoma (SCC) human papillomavirus
(HPV)þ patients who experience treatment failure and succumb to
distant metastasis.
Methods. Seventy-eight previously untreated patients nested in a
concurrent chemoradiation protocol were reviewed to correlate patterns of
local-regional tumor extent to distant metastasis. Biomarker assessment
was: HPV in situ hybridization and epidermal growth factor receptor
(EGFR) immunointensity.
Results. The 3-year disease-specific survival (DSS) for patients
presenting with and without matted nodes was 69% and 94%,
respectively (p ¼ .003). Matted nodes were a poor prognostic factor
independent of T classification, HPV, EGFR, and smoking status. For
patients who were HPVþ, 7 of 11 died of distant metastasis and 6 of 7
with distant metastasis had matted nodes.
Conclusion. Matted nodes are a novel marker of poor prognosis in
oropharyngeal SCC independent of established prognostic factors.
Matted nodes may identify patients at risk for the development of distant
metastasis who could benefit from systemic therapy, whereas patients
without matted nodes may be candidates for de-escalation of therapy.
VC 2012 Wiley Periodicals, Inc. Head Neck 34: 1727–1733, 2012
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Oropharyngeal squamous cell carcinoma (SCC) is a dis-
ease related to smoking and alcohol consumption. More
recently, it has been shown that high-risk human papillo-
mavirus (HPV) is associated with and is a causative factor
leading to oropharyngeal SCC.1 Patients who have HPV-
positive cancers and do not have a history of tobacco or
alcohol consumption have a better prognosis than patients
who are HPV-negative with a history of tobacco and/or
alcohol exposure.2–4
Despite better prognosis, there is still a group of
patients who are HPV-positive who experience treatment
failure and eventually succumb to their disease. Although
most studies confirm excellent locoregional control rates
with various treatment modalities,5 the incidence of treat-
ment failures from distant metastasis in patients with oro-
pharyngeal SCC has doubled over the past 20 years.6 Dis-
tant metastasis now accounts for approximately 45% of
deaths in patients with oropharyngeal SCC.3,7 It would be
beneficial to identify which subgroup of patients with
oropharyngeal SCC is at risk for distant failure in this
otherwise highly responsive group. Identifying these
patients before therapy could have significant implications
as treatment might be tailored in these patients to improve
overall survival.
At the University of Michigan, the majority of patients
with advanced-stage oropharyngeal SCC have been
treated within a nested clinical trial, allowing uniformity
when analyzing outcomes. We wanted to evaluate local-
regional tumor extent as well as molecular markers in
patients with oropharyngeal SCC that may be associated
with distant metastasis. We hypothesized that there would
be a correlation between certain patterns of local-regional
tumor extent with distant metastasis.
PATIENTS AND METHODS
Study population
This study was nested in a prospective phase II clinical
trial (UMCC 02-021) designed to evaluate the toxicity
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and efficacy of weekly concomitant carboplatin, paclitaxel,
and intensity-modulated radiation therapy for advanced-
stage (III, IV) oropharyngeal SCC between 2003 and 2007.
Patients were eligible if they had previously untreated,
advanced-stage (III, IV), pathologically confirmed SCC of
the oropharynx and had a pretreatment staging CT scan or
CT/positron emission tomography (CT/PET) scan available
for review within 4 weeks of starting treatment. Tumor
staging was routinely performed by clinical examination
and direct laryngoscopy in the operating room along with
pretreatment staging CT or CT/PET correlation. Disease in
all patients was staged based on the 2002 American Joint
Committee on Cancer staging system. Patients were
excluded if they had previous surgery or radiation therapy
to the upper aerodigestive tract or neck.
Pretreatment imaging
Pretreatment staging CT or CT/PET scans within 4
weeks of starting therapy were reviewed by a neuroradi-
ologist (M. I.) without knowledge of patient outcome. A
number of local-regional patterns were tabulated, includ-
ing primary tumor site and size, distance of the primary
tumor from the midline, and encasement of the carotid ar-
tery by the primary tumor. The size (largest 2 dimen-
sions) and distribution (level I–V) of each pathologic lymph
node was recorded for each level of the neck. N3 nodal dis-
ease was defined clinically as a lymph node or group of
lymph nodes greater than 6 cm. Matted nodes were 1 of the
nodal characteristics that were recorded and was defined as
3 nodes abutting one another with loss of intervening fat
plane that is replaced with evidence of extracapsular spread
(Figure 1). Extracapsular spread (ECS) was defined with
imaging as loss of the sharp plane between the capsule of
the lymph node and the surrounding fat.
Population characteristics
There were 87 consecutive patients who met the crite-
ria and were enrolled in this clinical trial. Nine patients
were excluded from this study because pretreatment
imaging was unavailable for review or they had exci-
sional lymph node biopsies before referral and staging
CT scan. Seventy-eight previously untreated patients
were identified, and baseline characteristics are shown in
Table 1. There were 70 male patients, and the average
age was 58.5 years. Matted nodes were observed in 21%
(16 of 78) of the population. The frequency of involved
subsites were 47% base of tongue (37 of 78), 51% tonsil
(40 of 78), and 1% posterior pharyngeal wall (1 of 78).
There were 37% (29 of 78) who had T4 tumors and 86%
(67 of 78) who were stage IV. Tobacco status was
defined categorically as never, prior (quit greater than 6
months before diagnosis), or current use of cigarettes,
cigars, pipe, chewing tobacco, snuff, or snus. There were
19 patients who were never tobacco users, 40 patients
were prior tobacco users, and 19 patients were current
tobacco users.
Treatment protocol
Patients were treated with radiation 5 days per week.
The prescribed doses were 70 gray (Gy) at 2.0 Gy per
fraction to gross disease and 59 to 63 Gy at 1.7 to 1.8 Gy
per fraction to low-risk and high-risk subclinical regions,
respectively, delivered concomitantly according to pub-
lished methods.8,9 Chemotherapy consisted of weekly car-
boplatin (area under the curve 1) intravenous over 30
minutes and paclitaxel 30 mg/m2 intravenous over 1
hour. Hydration and antiemetics were administered
according to the standard of care.
Tissue microarray and immunostaining
A tissue microarray (TMA) was constructed from pre-
treatment biopsies of the primary tumor for 73 of the 78
patients. Five patients did not have adequate tissue sam-
ples available for analysis. Tissue microarray slides were
processed by a previously described method.2 HPV status
was determined with in situ hybridization by a previously
described method using SensiGen LLC of Ann Arbor,
Michigan.10 Eighty-four percent of the patients (61 of 73)
were HPV positive.
Epidermal growth factor receptor (EGFR) intensity was
scored as follows: 1, equal to no staining; 2, low inten-
sity; 3, moderate; and 4, high intensity. Scores from 3
cores, 0.6 mm in diameter, were averaged from each
patient. EGFR-negative was defined as an averaged score
of less than 2.5 and EGFR-positive was defined as an
averaged score of 2.5 or greater. There were 41 patients
who were EGFR positive and 23 patients who were
EGFR negative. The pathologist was blinded to the clini-
cal outcome.
Statistical analysis
Outcomes of interest were overall survival (OS), dis-
ease-specific survival (DSS), and pattern of recurrence
(local, regional, or distant). Survival estimates were
defined from the date of diagnosis. An OS event was
defined as death from any cause; a DSS event was
defined as death from cancer, deaths from other causes
were censored at the date of death.
Bivariate associations between matted nodes and other
clinical variables were tested with exact tests (ie, Fisher
exact test, chi-square test with Monte Carlo estimates for
error terms). Survival estimates were computed using the
Kaplan–Meier method. Univariate associations with sur-
vival were tested with the log-rank test and multivariate
Cox models were used to test the association of matted
nodes with decreased survival after controlling for clini-
cal variables including age, T classification, tobacco sta-
tus, HPV status, and EGFR expression.
All patients provided written informed consent to par-
ticipate in the University of Michigan Specialized Pro-
gram of Research Excellence (SPORE) program and the
prospective clinical trial, which were approved by the
Institutional Review Board for human experimentation of
the University of Michigan.
RESULTS
The 3-year OS and DSS for the entire cohort were 84%
and 89%, respectively, with a median follow-up of 51
and 49 months. The 3-year DSS for patients who pre-
sented with matted nodes was 69% and for patients who
had no evidence of matted nodes it was 94% (Figure 2;
p ¼ .0001).
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In the HPV-positive population, matted nodes were a
prognostic factor for poor outcome (Figure 3A; p ¼ .0004).
There were 61 patients who were HPV positive, of which
10 had matted nodes. Of the 10 of 61 patients who were
HPV positive and had matted nodes, 6 of 10 (60%) died of
their disease. Of the 51 of 61 patients who were HPV posi-
tive and had no evidence of matted nodes, 5 of 51 (9.8%)
died of their disease.
In the HPV-negative population, there was no signifi-
cant difference in DSS when stratifying by matted nodes
(Figure 3B; p ¼ .62). There were 12 patients who were
HPV negative, of which 5 had matted nodes. Of the 5 of
12 patients who were HPV negative and had matted
nodes, 2 of 5 (40.0%) died of their disease. Of the 7 of
12 patients who were HPV negative and had no evidence
of matted nodes, 1 of 7 (14.3%) died of their disease.
FIGURE 1. CT scans demonstrating examples of matted nodes (A–C) and non-matted nodes (D–F). (A–C) Shows examples of patients with matted
nodes demonstrated by the corresponding arrows. (A) Shows 3 matted nodes in level II of the left neck (arrow). (B) Shows 2 nodes with cystic
degeneration and loss of intervening fat plane in level II of the right neck (arrow). There is a third node with loss of intervening fat plane on more
inferior images not demonstrated on this radiograph. (C) Shows 3 matted nodes in level III of the left neck (arrow). (D–F) Shows examples of
patients with nonmatted nodes demonstrated by arrows. (D) Shows a single large cystic node in level II of the left neck (arrow). (E) Shows 2 nodes
with loss of intervening fat plane in level II/III of the right neck (arrow). There are no lymph nodes seen at other levels. (F) Shows a single large
node in level II of the left neck (arrow).
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Given the observed differences in survival, a powered
analysis of a larger cohort of patients who are HPV nega-
tive is warranted.
Matted nodes were not a surrogate marker for N3 neck
disease. There were 10 patients with N3 disease, of which
5 had matted nodes. Of the patients with N3 disease and
matted nodes, 60% (3 of 5) died of their disease com-
pared with 20% (1 of 5) of patients with N3 disease and
no evidence of matted nodes. In patients with N2b dis-
ease, there were 29 patients, of which 6 had matted
nodes. Of the patients with N2b with matted nodes, 3 of
6 (50%) died of their disease, and 3 of 23 (13%) with no
evidence of matted nodes died of their disease. In the
N2c group, there were 18 patients, of which 5 have mat-
ted nodes. Of the patients with matted nodes, 4 of 5
(80%) died of their disease and 3 of 13 (23%) with no
evidence of matted nodes died of their disease.
Distant metastasis was more common in patients with
matted nodes, whereas patients with no evidence of mat-
ted nodes were more likely to develop a local recurrence
(Table 2). There were 16 patients with matted nodes, 10
of these patients died (62%). Of the patients with matted
nodes who died, the cause of death was lung metastasis
in 8 of 10 patients. In the HPV-positive cohort, 7 of 61
patients died of distant metastasis and 6 of the 7 patients
that died of distant metastasis had matted nodes.
The patients with the best prognosis were the HPV pos-
itive nonsmokers. There were 16 never smokers who
were HPV positive, 2 patients died of their disease in this
cohort. Both patients had matted nodes and died of dis-
tant metastasis.
Matted nodes were an independent prognostic factor of
poor outcome among the current or previous tobacco-use
population (p ¼ .03). There were 59 patients who were
current or previous tobacco users; 14 of them had matted
nodes. Of the 14 of 59 patients who were previous or
current tobacco users and had matted nodes, 6 of 14
(42.9%) died of their disease. Of the 45 of 59 patients
who were previous or current tobacco users and had no
evidence of matted nodes, 6 of 45 (13.3%) died of their
disease. Interestingly, 14 of 16 patients who had matted
nodes were previous or current tobacco users.
Matted nodes were also a poor independent prognostic
factor in the EGFR-positive population (Figure 4; p ¼
.002). There were 41 patients who were EGFR-positive, 5
of them had matted nodes. Of the 5 of 41 patients who
were EGFR positive and had matted nodes, 3 of 5 (60%)
died of their disease. Of the 36 of 41 patients who were
EGFR positive and had no evidence of matted nodes, 3
of 36 (8%) died of their disease. There were 24 patients
in the EGFR-negative population and there was no signif-
icant difference in DSS when stratifying by matted nodes.











Age, mean (SD) 58.4 (9.2) 58.5 (8.4) .97
Subsite .83
BOT 44% (7) 48% (30)
Tonsil 56% (9) 50% (31)
Postpharyngeal wall 0% (0) 2% (1)
Overall stage .11
III 0% (0) 18% (11)
IV 100% (16) 82% (51)
T classification .002
T1 0% (0) 10% (6)
T2 25% (4) 39% (24)
T3 0% (0) 24% (15)
T4 75% (12) 27% (17)
N classification .02†
N0 0% (0) 11% (7)
N1 0% (0) 13% (8)
N2a 0% (0) 10% (6)
N2b 38% (6) 37% (23)
N2c 31% (5) 22% (13)
N3 31% (5) 8% (5)
HPV status .05
Positive 63% (10) 82% (51)
Negative 31% (5) 11% (7)
Missing 6% (1) 7% (4)
EGFR status .1
Positive 31% (5) 58% (36)
Negative 38% (6) 27% (17)
Missing 31% (5) 15% (9)
Tobacco status .18
Never 12% (2) 27% (17)
Prior 44% (7) 53% (33)
Current 44% (7) 20% (12)
Abbreviations: BOT, base of tongue; HPV, human papillomavirus; EGFR, epidermal growth
factor receptor.
* The p value tests association with matted node category for each variable. Fisher exact test
is used for dichotomous variables. Likelihood ratio chi-square test with Monte Carlo estima-
tion of errors is used for variables with more than 2 levels. Missing values are excluded.
†We expect this difference to be present since matted nodes are defined by characteristics
present only in N2b or worse patients.
FIGURE 2. Kaplan–Meier survival curves of the entire cohort
stratified by the presence of matted nodes. The 3-year disease-
specific survival (DSS) for matted nodes patients was 69% and
for patients with no evidence of matted nodes was 94% (p ¼
.0001). [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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A multivariate analysis was performed and matted
nodes remained an independent predictor of poor progno-
sis after controlling for T classification, HPV status,
EGFR expression, and tobacco status (DSS; hazard ratio
¼ 9.46; 95% confidence interval, 1.52–59.06; p ¼ .016).
DISCUSSION
In this cohort, matted nodes are a novel marker of poor
prognosis in oropharyngeal SCC and are independent of
other established prognostic factors. Furthermore, matted
nodes can identify patients before treatment who are at
high risk for failure due to distant metastasis, particularly
in the HPV-positive population.
The epidemiology of oropharyngeal SCC has been
redefined over the last decade. HPV, smoking, alcohol,
and cannabis have all been identified as etiologic agents for
the development of oropharyngeal SCC. As research has
proceeded, a complex interplay between HPV infection,
amount of smoking behavior, and bulk of disease has been
described.3 In the current study, the finding of matted nodes
shows promise for quantifying important versus less impor-
tant "bulk of disease.’’ Our findings suggest that matted
nodes may be an important predictor of survival that is inde-
pendent of HPV, EGFR, and smoking status. Matted nodes
were more prevalent in the HPV-negative cohort (5 of 12)
than the HPV-positive cohort (10 of 61) and were associated
with distant metastasis in both groups. This correlation
advances the determination of risk factors for treatment fail-
ure in oropharyngeal SCC and contributes to identifying
patients who are at risk for distant metastasis and may
require more systemic treatment.
Our patient population was derived from a prospective
cohort of patients treated in a uniform prospective chemo-
therapy and intensity-modulated radiation therapy protocol.
It should be noted that our protocol incorporated concomi-
tant carboplatin and paclitaxel with radiotherapy, which
could be inferior to concurrent cisplatin in patients with
matted lymph nodes. Such high-dose regimens, perhaps
with induction chemotherapy, may be more efficacious in
patients with poor prognostic clinical features.11
Given the well-established survival benefit in the HPV-
positive cohort, the Radiation Therapy and Oncology Group
is beginning trials to de-escalate therapy in these patients to
minimize treatment-related effects. The finding of matted
nodes may help to identify patients who are likely to fail
concomitant chemotherapy and radiation therapy and might
be considered for exclusion or stratification in such de-esca-
lation trials. Conversely, the 3-year DSS in the HPV-posi-
tive cohort with no evidence of matted nodes was 90%.
This subgroup has an excellent prognosis and consideration
of de-escalated treatment would seem to be warranted.
ECS and tumor burden are also considered negative
prognostic factors in oropharyngeal SCC.3,12 Matted
nodes are distinct from ECS and N3 neck disease, con-
veying a worse prognosis independent of these conven-
tional clinical predictors. ECS was defined radiographi-
cally in this study because pathologic confirmation was
not possible because all patients were managed nonsur-
gically. When Carvalho et al13 reviewed CT scans and
then correlated their pathologic specimens in patients
with head and neck SCC, they found that a CT scan was
only able to detect 10 of 16 patients who had ECS in
their pathologic specimens. Therefore, it is possible that
we have overestimated the prevalence of ECS based on
radiologic findings. The incidence of ECS with imaging
in our study was 74% (58 of 78). As a comparison to
recently published surgical cohorts, Weinstein et al14
and Rich et al15 reported an incidence of ECS in patho-
logic specimens of 41% and 85%, respectively. Of
course, these comparisons are difficult because ECS is a
continuum ranging by location and degrees of micro-
scopic through macroscopic spread.
FIGURE 3. (A) Kaplan-Meier survival curves of patients with
human papillomavirus (HPV)-positive stratified by matted nodes.
For the patients who were HPV-positive with matted nodes, all of
6 deaths were due to distant metastasis. (B) Kaplan-Meier
survival curves of patients who were HPV-negative stratified by
matted nodes (p ¼ .62). There was limited power given the
sample size of this cohort. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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While we cannot explain the mechanism for the sur-
vival difference in patients with N3 disease with and
without matted nodes, this is most likely due to differen-
ces in tumor biology. Histologic confirmation of cancer
and/or ECS in the imaged lymph nodes was not possible
in this study because these patients were managed non-
surgically. Thus, there is the possibility that some of the
imaged lymph nodes could have been inflammatory in
nature or associated with a significant immunologic
response in the nodes. The biologic behavior of cancer in
patients with matted nodes may reflect a propensity to
spread into multiple regional lymph nodes as well as dis-
tant sites. Whether this is due to differences in inherent
metastatic characteristics or alterations in host immunity
remains conjecture. It is possible that there are molecular
differences between the primary and the matted lymph
nodes. Confirmatory studies are needed when pathologic
tissue is available to delineate the biologic differences of
these tumors.
In this cohort, multiple marker analysis is limited due
to sample size. Nevertheless, multivariable analysis did
suggest that, despite the wide confidence interval, matted
nodes were associated with a poor prognosis controlling
for T classification, HPV, and EGFR status, as well as
tobacco use.
Matted nodes are associated with poor prognosis in
oropharyngeal SCC independent of other known clinical
and molecular markers. Matted nodes may identify a
group of patients who frequently develop distant metasta-
sis and who may benefit from systemic therapy, whereas
patients in low-risk populations with no evidence of mat-
ted nodes may benefit from de-escalation of therapy.
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